BioCentury | Jan 30, 2006
Company News

Novexel management update

...Romainville, France Business: Infectious Hired: Gordon Waldron as CFO, formerly VP and CFO at Synt:em S.A. WIR...
BioCentury | Jun 27, 2005
Product Development

Insulin rush

...the company will soon begin preclinical testing of an MS candidate in concert with partner Synt:em S.A....
BioCentury | Apr 18, 2005
Clinical News

Syn1001 neurology data

...from a double-blind study showed that Syn1001 was transported across the blood brain barrier. Additionally, Synt:em...
BioCentury | Mar 21, 2005
Company News

Sonus, Synt:em deal

...Sonus Pharmaceuticals Inc. (SNUS), Bothell, Wash. Synt:em S.A. , Nimes, France Business: Drug delivery, Neurology, Cancer SNUS...
...Nimes, France Business: Drug delivery, Neurology, Cancer SNUS terminated its proposed stock acquisition of Synt:em...
BioCentury | Mar 21, 2005
Finance

Ebb & Flow

...on the week on news that it won't proceed with a planned stock acquisition of Synt:em...
BioCentury | Mar 21, 2005
Analyst Picks & Changes

Analyst picks & changes

...19% $3.12 Kaplan upgraded the stock on news that SNUS terminated its planned acquisition of Synt:em...
BioCentury | Mar 16, 2005
Company News

Sonus terminates Synt:em acquisition

...SNUS terminated its previously proposed stock acquisition of Synt:em (Nimes, France). SNUS said it wants to...
BioCentury | Jan 3, 2005
Company News

Sonus, Synt:em deal

...Sonus Pharmaceuticals Inc. (SNUS), Bothell, Wash. Synt:em S.A. , Nimes, France Business: Drug delivery, Neurology, Cancer The...
...Business: Drug delivery, Neurology, Cancer The companies revised the terms of SNUS's proposed acquisition of Synt:em...
...issue $10 million. The rest of the shares will be issued as contingent milestones when Synt:em...
BioCentury | Nov 15, 2004
Strategy

Sonus reaches an event horizon

...Sonus Pharmaceuticals Inc. 's proposed acquisition of Synt:em S.A. is one of a succession of near-term events...
...product, Tocosol paclitaxel, along with a partnership for the compound. In addition, SNUS believes the Synt:em...
...plans to maintain Synt:em as a wholly owned subsidiary, retaining all 38 employees. Michel Kaczorek, Synt:em's...
BioCentury | Nov 8, 2004
Finance

Analyst picks & changes

...Kaplan Price target Accumulate Kaplan lowered his target to $7 from $18. He called the Synt:em...
Items per page:
1 - 10 of 47
BioCentury | Jan 30, 2006
Company News

Novexel management update

...Romainville, France Business: Infectious Hired: Gordon Waldron as CFO, formerly VP and CFO at Synt:em S.A. WIR...
BioCentury | Jun 27, 2005
Product Development

Insulin rush

...the company will soon begin preclinical testing of an MS candidate in concert with partner Synt:em S.A....
BioCentury | Apr 18, 2005
Clinical News

Syn1001 neurology data

...from a double-blind study showed that Syn1001 was transported across the blood brain barrier. Additionally, Synt:em...
BioCentury | Mar 21, 2005
Company News

Sonus, Synt:em deal

...Sonus Pharmaceuticals Inc. (SNUS), Bothell, Wash. Synt:em S.A. , Nimes, France Business: Drug delivery, Neurology, Cancer SNUS...
...Nimes, France Business: Drug delivery, Neurology, Cancer SNUS terminated its proposed stock acquisition of Synt:em...
BioCentury | Mar 21, 2005
Finance

Ebb & Flow

...on the week on news that it won't proceed with a planned stock acquisition of Synt:em...
BioCentury | Mar 21, 2005
Analyst Picks & Changes

Analyst picks & changes

...19% $3.12 Kaplan upgraded the stock on news that SNUS terminated its planned acquisition of Synt:em...
BioCentury | Mar 16, 2005
Company News

Sonus terminates Synt:em acquisition

...SNUS terminated its previously proposed stock acquisition of Synt:em (Nimes, France). SNUS said it wants to...
BioCentury | Jan 3, 2005
Company News

Sonus, Synt:em deal

...Sonus Pharmaceuticals Inc. (SNUS), Bothell, Wash. Synt:em S.A. , Nimes, France Business: Drug delivery, Neurology, Cancer The...
...Business: Drug delivery, Neurology, Cancer The companies revised the terms of SNUS's proposed acquisition of Synt:em...
...issue $10 million. The rest of the shares will be issued as contingent milestones when Synt:em...
BioCentury | Nov 15, 2004
Strategy

Sonus reaches an event horizon

...Sonus Pharmaceuticals Inc. 's proposed acquisition of Synt:em S.A. is one of a succession of near-term events...
...product, Tocosol paclitaxel, along with a partnership for the compound. In addition, SNUS believes the Synt:em...
...plans to maintain Synt:em as a wholly owned subsidiary, retaining all 38 employees. Michel Kaczorek, Synt:em's...
BioCentury | Nov 8, 2004
Finance

Analyst picks & changes

...Kaplan Price target Accumulate Kaplan lowered his target to $7 from $18. He called the Synt:em...
Items per page:
1 - 10 of 47